Zhejiang Orient Gene Biotech Co.Ltd(688298) the pace of globalization is accelerating. After announcing that the American company will realize the intensive development of production, R & D, sales and laboratory in 2022, its British subsidiary is expected to be put into production and operation in about a month.
In February 5th, the official account of Zhejiang Orient Gene Biotech Co.Ltd(688298) WeChat public came 2nd anniversary. Zhejiang Orient Gene Biotech Co.Ltd(688298) chairman Fang Jianqiu and general manager Fang Xiao Liang released the letter to all shareholders and employees. According to the letter, Hengjian, a wholly-owned subsidiary located in Houston, USA, has developed rapidly and has basically formed a diversified development pattern of R & D, production, sales and third-party testing. The subsidiary in Vancouver, Canada has developed steadily. AGCO biotechnology company has been newly established in Scotland, UK, and is expected to be officially put into production and operation in about a month.
At the beginning of December last year, Zhejiang Orient Gene Biotech Co.Ltd(688298) invested US $5 million in Scotland to set up a wholly-owned subsidiary of Aike biology. It is reported that Aike biological will set up a manufacturing plant in Arroway, Scotland, mainly producing covid-19 antigen, antibody and nucleic acid detection reagents, as well as various respiratory tract, digestive tract and other infectious disease detection reagents, drug detection reagents, tumor markers and gene mutation detection reagents, as well as supporting high-end detection instruments. The establishment of Aike biology has laid a foundation for Zhejiang Orient Gene Biotech Co.Ltd(688298) to integrate into the UK and European markets and provide technology, products and services.
In addition, Zhejiang Orient Gene Biotech Co.Ltd(688298) American industrial base will also realize production and sales this year. Last month, Fang Xiaoliang revealed in his speech at the Zhejiang Orient Gene Biotech Co.Ltd(688298) annual meeting that Hengjian, a wholly-owned subsidiary, has begun to layout its industrial base in Houston and will realize the intensive development of production, R & D, sales and laboratory in 2022.
